ActiveSight Signs Expanded Crystallography Service Agreement with Lexicon Pharmaceuticals
News Jan 09, 2007
ActiveSight announced that it has signed an expanded crystallography services agreement with Lexicon Pharmaceuticals. The agreement, the third between the companies, covers co-crystallography services for multiple proprietary targets of Lexicon Pharmaceuticals.
ActiveSight's second co-crystallography agreement with Lexicon was announced in April of 2005. Lexicon Pharmaceuticals is the medicinal chemistry division of Lexicon Genetics Incorporated.
"We are delighted that Lexicon Pharmaceuticals has decided to expand their relationship with ActiveSight. We look forward to providing continued structural biology support for Lexicon's drug discovery programs," stated Duncan McRee, President of ActiveSight.
3rd International Conference and Exhibition on Nanomedicine and Drug Delivery
Mar 13 - Mar 14, 2019
International Conference on Cell and Structural biology
Jul 15 - Jul 16, 2019